Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Chemotherapy-Related Adverse Events Add to Economic Burden in Metastatic Breast Cancer

TOP - October 2012 VOL 5, NO 7 published on November 13, 2012 in Breast Cancer
Caroline Helwick

Adverse events (AEs) related to chemotherapy for metastatic breast cancer (MBC) create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said Sara A. Hurvitz, MD, of the University of California Los Angeles, who presented an economic analysis at the 2012 Annual Meeting of the American Society of Clinical Oncology.

“In addition, an analysis of healthcare costs stratified by the number of AEs reported by patients showed a clear trend: the economic burden of AEs increases with the number of AEs reported,” she added.

The study is the first to assess costs associated with AEs that occur during treatment for MBC, she said.

Hurvitz led a study sponsored by Genentech that aimed to quantify the economic impact of AEs reported in patients with MBC receiving first- or second-line therapy with taxanes or capecitabine for at least 30 days per treatment episode. Patients were selected from the PharMetrics Integrated Database. The data elements included pharmacy and medical claims from more than 100 healthcare plans in the United States, covering more than 70 million lives between 2000 and 2010.

The eligible cohort included 3222 patients who used a taxane (docetaxel, paclitaxel) first-line (n = 1866), capecitabine first-line (n = 812), taxane second-line (n = 715), or capecitabine second-line (n = 369). Patients treated with both classes during the same episode were excluded. The AE list included almost 2 dozen possible AEs.

AEs were commonly seen in each of the 4 study cohorts. With taxanes, 94.6% of first-line patients and 94.4% of second-line patients experienced at least 1 event during treatment. With capecitabine, 83.7% and 84.0%, respectively, experienced at least 1 AE. Nausea/vomiting was the most common complication with either agent, Hurvitz reported.

In general, patients who experienced no AEs in the study were relatively younger and had fewer comorbidities at baseline.

Incremental Monthly Costs Associated With AEs
The incremental costs associated with chemotherapy-related complications were estimated by comparing the average costs between the cohorts with AEs and without AEs for the 4 treatment groups. The analysis revealed the following:

  • Taxanes first-line: AEs were associated with a 38.7% increase in monthly costs, over patients without AEs ($3547). These incremental costs were mainly driven by increased inpatient costs and other drug costs (other than chemotherapy).
  • Taxanes second-line: AEs were associated with a 69.5% increase in monthly costs ($5320). Incremental costs were mainly driven by incremental pharmacy costs for chemo­therapy and other drugs.
  • Capecitabine first-line: AEs were associated with a 9% increase in monthly costs ($4933). Incremen­tal costs were mainly driven by inpatient and outpatient costs.
  • Capecitabine second-line: AEs were associated with an 82.9% increase in monthly costs ($4933). Incre­men­tal costs were mainly driven by inpatient and outpatient costs.

Increasing AEs per Episode Led to Higher Costs
The more AEs per episode, the greater the cost of care, the analysis further found. For example, for taxane first-line therapy, the mean cost for a treatment without an AE episode was approximately $10,000, which rose to approximately $11,000 in the setting of 1 or 2 AEs and to almost $15,000 in the setting of more than 4 AEs.

For second-line capecitabine, treatment without an AE episode cost approximately $6000, but rose to approximately $14,000 in the setting of more than 4 AEs.

The average monthly costs per type of AE were highest for skin toxicity with taxanes and for constitutional symptoms with capecitabine, both approaching $16,000 on average.

Hurvitz cautioned that the study has limitations: cause-and-effect associations cannot be confirmed and the reported rates are restricted to duration of an episode of treatment and did not take into account complications occurring after treatment ended. It is also a retrospective observational study based on claims data, though this also has the advantage of being a valid, large sample-source of clinical practice data, she pointed out.

“Further research evaluating the clinical and economic consequences of chemotherapy-related AEs in a pro­spec­tive manner can further characterize the effects seen here,” she said.

Related Items
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Updates
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Updates, In the News
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Yvette Florio Lane
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Yvette Florio Lane
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Updates, In the News
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Last modified: April 27, 2020